Final results of a prospective multi-institutional phase II study of everolimus (RAD001), an mTor inhibitor, in pediatric patients with recurrent or progressive low-grade glioma. A POETIC consortium trial - Kieran, M W; Yao, X; Macy, M (Neuro Oncol, 2014)
, et al.